p53 single nucleotide polymorphisms and bladder cancer

Area of Science:

• Genetics
• Oncology
• Molecular Biology

Background:

• The tumor suppressor gene p53 plays a crucial role in preventing cancer.
• Germline p53 polymorphisms may influence individual susceptibility to various cancers, including bladder cancer.
• Understanding these genetic variations can aid in risk assessment and personalized medicine.

Purpose of the Study:

• To investigate the association between two specific p53 germline polymorphisms (BstUI and MspI) and the risk of bladder cancer.
• To determine if these polymorphisms affect the distribution of genotypes in bladder cancer patients compared to healthy controls.

Main Methods:

• Polymerase chain reaction (PCR) based methods were employed to analyze p53 germline polymorphisms.
• The study included 50 patients diagnosed with bladder cancer and 145 healthy individuals serving as controls.
• Genotyping for BstUI (exon 4) and MspI (intron 6) polymorphisms was performed.

Main Results:

• Increased frequencies of BstUI and MspI A2 alleles were observed in bladder cancer patients, but these associations were not statistically significant (p=0.2308 and p=0.5959, respectively).
• A statistically significant difference was found in the distribution of MspI genotypes between patients and controls (p=0.0354).
• Specifically, a lower proportion of the heterozygous MspI A1A2 genotype was noted in bladder cancer patients compared to controls.

Conclusions:

• The p53 BstUI and MspI germline polymorphisms appear to marginally modify the risk of developing bladder cancer.
• The observed significant difference in MspI genotype distribution warrants further investigation into its role in bladder cancer etiology.
• These findings contribute to understanding the genetic underpinnings of bladder cancer susceptibility.